meta_pixel
Tapesearch Logo
Log in
The Peter Attia Drive

#290 ‒ Liquid biopsies for early cancer detection, the role of epigenetics in aging, and the future of aging research | Alex Aravanis, M.D., Ph.D.

The Peter Attia Drive

Peter Attia, MD

Health & Fitness, Medicine, Fitness

4.77.3K Ratings

🗓️ 19 February 2024

⏱️ 126 minutes

🧾️ Download transcript

Summary

View the Show Notes Page for This Episode

Become a Member to Receive Exclusive Content

Sign Up to Receive Peter’s Weekly Newsletter

Alex Aravanis is a leader in research and development of technologies and clinical tests utilizing the latest tools in DNA analysis and data science. In this episode, Alex delves into two interconnected topics: liquid biopsies and epigenetics. He begins by tracing the trajectory of genome sequencing and tumor sequencing, setting the stage for a detailed exploration of liquid biopsies as an early cancer detection method. The discussion encompasses key concepts such as cell-free DNA, DNA methylation, sensitivity, specificity, and the predictive values associated with liquid biopsies. Transitioning to epigenetics, Alex examines the intricate interplay of DNA methylation and aging biology and explores the possibility of using cellular reprogramming to reverse epigenetic changes that occur with aging.

We discuss:

  • Alex’s background in applying engineering to problems in medicine [3:15];
  • A primer on human genetics, and the history and current landscape of DNA sequencing [11:00];
  • The advent and evolution of liquid biopsies for early detection of cancer [23:15];
  • The role of cell-free DNA in cancer detection: how incidental findings in non-invasive prenatal testing led to the development of liquid biopsies [40:15];
  • The development of a universal blood test for cancer detection and a discussion of specificity of tests [46:00];
  • Advancements in cell-free DNA analysis and development of a multi-cancer screening test at GRAIL [51:00];
  • DNA methylation explained [58:15];
  • Optimizing cancer detection with methylation analysis of cfDNA in small blood samples [1:02:45];
  • The importance of understanding sensitivity, specificity, positive predictive value, and negative predictive value in cancer screening [1:08:00];
  • The performance of the GRAIL Galleri test and its ability to detect various types and stages of cancer [1:21:00];
  • Do early cancer detection methods, like liquid biopsies, translate to improvement in overall survival? [1:27:45];
  • The role of epigenetics in aging [1:39:30];
  • How cell-free DNA methylation patterns can help identify a cancer’s tissue of origin [1:45:30];
  • Cellular and epigenetic reprogramming and other exciting work in the field of aging [1:52:30]; and
  • More.

Connect With Peter on Twitter, Instagram, Facebook and YouTube

Transcript

Click on a timestamp to play from that location

0:00.0

Hey everyone. Welcome to the Drive Podcast. I'm your host, Peter Attia. This

0:15.7

podcast, my website, and my weekly newsletter all focus on the goal of

0:19.6

translating the science of longevity into something accessible for everyone.

0:24.0

Our goal is to provide the best content in health and wellness,

0:27.0

and we've established a great team of analysts to make this happen.

0:31.0

It is extremely important to me to provide all of this content without relying

0:34.9

on paid ads. To do this, our work is made entirely possible by our members, and in return,

0:40.3

we offer exclusive member-only content and benefits above and beyond what is available for free.

0:46.0

If you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of a subscription.

0:54.0

If you want to learn more about the benefits of our premium membership,

0:58.0

head over to Peter AttiaMD.com

1:01.0

forward slash subscribe

1:04.7

My guest this week is Alex Aravinus.

1:06.9

Alex is the CEO and co-founder of Moonwalk Biosciences.

1:11.5

I should note up front that I am also an investor in and an advisor to

1:15.9

Moonwalk Biosciences. Alex and I were colleagues in medical school so I've known

1:20.9

Alex for a little over 25 years now. Before Moonwalk, Alex was

1:25.0

Alumina's chief technology officer, the SVP and head of research and product

1:30.2

development. And under his leadership, Alumina launched the industry leading product for generating

1:35.8

and analyzing most of the world's genomic data.

1:38.3

He developed large genome-based research and clinical applications,

1:42.2

including whole genome sequencing for rare disease diagnoses,

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from Peter Attia, MD, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Peter Attia, MD and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2025.